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The crystallization of Anti-CD20, a full-length monoclonal antibody, has been studied in the PEG400/
na2So4/Water system near Liquid-Liquid Phase Separation (LLPS) conditions by both sitting-drop 
vapour diffusion and batch methods. In order to understand the Anti-CD20 crystallization propensity in 
the solvent system of different compositions, we investigated some measurable parameters, normally 
used to assess protein conformational and colloidal stability in solution, with the aim to understand 
the aggregation mechanism of this complex biomacromolecule. We propose that under crystallization 
conditions a minor population of specifically aggregated protein molecules are present. While this minor 
species hardly contributes to the measured average solution behaviour, it induces and promotes crystal 
formation. The existence of this minor species is the result of the LLPS occurring concomitantly under 
crystallization conditions.
A thorough understanding of protein aggregation behaviour in solution is crucial for the controlled manufacture 
and formulation of therapeutics and for the development of crystallization-based purification strategies for bio-
logical drugs1–4. Unfortunately, while the state diagram of protein-solvent systems can provide indications about 
the phase behaviour of biomacromolecules and their stability in solution, the intimate mechanism underlying 
protein nucleation and crystal growth have not been fully understood yet and, in many cases, it remains elusive. 
Protein aggregation is directly related to protein-protein interactions and may be strongly related to protein crys-
tallization behaviour5. Since different types of intermolecular forces are involved in protein interactions, such as 
electrostatic, van der Waals and hydrophobic6, environmental factors like pH, ionic strength and the presence of 
additives, can drastically alter the intermolecular interaction profile of proteins in solution7,8.
Colloidal and conformational stabilities are the two main factors that govern the existence of a protein aggre-
gate in a solution9,10. Colloidal stability is a delicate balance between repulsive and attractive forces between pro-
teins, while conformational stability is related to the free energy difference between two molecular states, folded 
and partially or totally unfolded. Several investigations have found that the melting temperature (Tm) and the 
osmotic second virial coefficient (B22) can respectively account for the protein conformational11 and colloidal12 
stability. Both Tm and B22 can be experimentally determined by using correspondingly Dynamic Light Scattering 
(DLS) and Static Light Scattering (SLS) methods13. Aggregation induced by thermal unfolding can be monitored 
by measuring the average hydrodynamic diameter value as a function of temperature, while B22 describes the first 
deviation from ideal behaviour of dilute colloidal solutions14. A positive or negative value of B22 accounts for a net 
repulsive or attractive interaction balance, respectively, and could therefore be used to predict stable, crystallizing 
or precipitating protein solution conditions. According to the experimental crystallization slot of George and 
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Wilson15, a protein solution would be: stable if B22 > −0.8 × 10−4 mL mol g−2; crystallizing if −8.4 × 10−4 < B22 < 
−0.8 × 10−4 mL mol g−2; precipitating if B22 < −8.4 × 10−4 mL mol g−2. Haas and Drenth16 postulated a modified 
crystallization slot, ranging from −0.9 × 10−4 to −0.35 × 10−4 mol mL g−2 for protein with a molecular size as 
high as 140 kDa.
The Z-potential is another indicator of colloidal stability, which measures the magnitude of the electrostatic or 
charge repulsion/attraction between particles17. It is related to the surface charge of the molecules, the adsorbed 
layer at the interface and the nature and composition of the surrounding environment. A large Z-potential value 
(|Z-potential| >30 mV) can be considered an indicator of colloidal stability. Recently, the use of the interac-
tion parameter kd has been also suggested as a more high-throughput means to quantify protein-protein 
interactions18,19.
In this work, we focus on the relationships between the crystallization propensity of Anti-CD20 in the 
Na2SO4/PEG400 solvent system of different compositions and its relation with some measurable parameters 
normally used to assess protein conformational and colloidal stability in solution, with the aim to understand 
the aggregation mechanism of this complex biomacromolecule. Anti-CD20 is a full-length monoclonal anti-
body (mAb) and it is a therapeutic protein extensively used for treatment of chronic lymphocytic leukaemia and 
non-Hodgkin’s lymphoma, which is commercialized with the brand name of Rituxan or Mabthera. Here, the crys-
tallization of this biomolecule has been observed in a PEG400/Na2SO4/Water system near Liquid-Liquid Phase 
Separation (LLPS) conditions by both vapour diffusion and batch methods. LLPS is a very common phenomena 
for monoclonal antibodies20 and is of great interest because the factors which induce the separation of protein 
solutions into coexisting protein-poor and protein-rich phases are observed to play a central role in protein 
interaction and crystallization21. For several protein/PEG or protein/salt systems both the LLPS and the aggre-
gation propensity of proteins in solution have been shown to coincide with net attractive interactions between 
molecules22–24. Monte Carlo simulations performed on systems that undergo phase separation demonstrated 
that the interactions between the proteins fall into the short-range regime and are strongly anisotropic25. Over 
time, the anisotropic interactions may be responsible for the evolution of the system from the phase separation to 
reversible aggregation conditions. In this situation, the LLPS has been speculated to behave as a metastable state 
towards nucleation26–28. In fact, the pathway for the formation of crystal nuclei drastically changes near the meta-
stable low density–high density liquid region coexistence, with the free-energy barrier for crystal nucleation being 
strongly reduced. In this scenario, the crystal nucleation rate increases by many orders of magnitude over that 
predicted from classical nucleation theory28, thus generating a fast and diffuse crystallization that often results in 
poor-quality crystals.
The results of this investigation allowed us to gain further insights into the mechanism governing the 
nucleation-crystallization of a complex system such as the Anti-CD20 mAb.
Methods
Anti-CD20 crystallization experiments. Anti-CD20 monoclonal antibody (MW = 144.5 kDa) was kindly 
provided by FUJIFILM Diosynth Biotechnologies (Billingham, UK) at high level of purity (>98% HPLC, >95% 
SDS-PAGE) in 0.025 M sodium citrate buffer at pH 6.5 and 0.154 M sodium chloride solution. Sodium sulphate 
anhydrous (purity ≥ 99.99%), PEG400, HEPES (purity ≥ 99.5%), TRIS (purity ≥ 99.5%), magnesium chloride 
hexahydrate (≥99%) and NaOH (purity ≥ 98%), from Sigma-Aldrich (Italy), were used without further purifica-
tion. MilliQ water was used to prepare all solutions. Anti-CD20 was thawed for 2–3 hours in an 8 °C water bath 
before buffer exchange with HEPES 0.1 M and concentration by Amicon Ultra centrifugal filter tube (Ultra-4, cut-
off 10 kDa, from Merck) at 6,000 g and 8 °C. Finally, the protein solution was diluted to the desired concentration 
by adding HEPES buffer 0.1 M. NaOH 1 M was used to adjust the pH to the desired value. The Anti-CD20 con-
centration was determined by measuring protein absorbance at 280 nm by UV-Vis spectrophotometer (extinction 
coefficient at 280 nm 237,380 M−1 cm−1).
Protocols suitable for crystallizing Anti-CD20 reproducibly by vapour diffusion and batch methods were 
developed in previous works29,30. Precipitant solutions were made by dissolving sodium sulphate in the HEPES 
buffer solution containing PEG400 at the proper concentration. All solutions were filtered through a 0.22 µm 
Anotop 10 Filter Unit (Whatman). In sitting-drop vapour diffusion crystallization experiments, drops made of 
10 μL of precipitant solution and 10 μL of protein solutions were equilibrated in a sealed well against 1 mL of a 
hypertonic solution of MgCl2·6H2O 30 wt.% used as reservoir. For the batch crystallization experiments, a volume 
of protein solutions having a certain initial concentration was mixed with the required volume of precipitant 
solution to obtain a supersaturated solution of known composition (final volume 1 mL). All crystallization exper-
iments were performed in a vibration-free refrigerator at 20 °C.
Analysis of Anti-CD20 crystals. Crystals obtained from crystallization experiments were observed using 
an optical microscope (Eclipse LV 100ND, Nikon Instruments, Italy) equipped with a video camera, separated 
from the mother liquor by using a centrifuge (MiniSpin Plus Eppendorf model IVD) and centrifuge tubes 
(0.22 µm pore size) and extensively washed. Washing solution was made by 0.1 M HEPES, Na2SO4 and PEG400 
whose concentration was optimized to avoid crystal solubilisation according to standard procedures. Washed 
crystals were dissolved by using 0.01 M TRIS-HCl, NaCl 0.15 M, pH 8.0 and analysed by UV spectrophotometry 
(Lambda EZ201, Perkin Elmer) to estimate protein concentration.
Circular dichroism (CD) measurements. The far-UV CD spectra of Anti-CD20 under initial conditions, 
after buffer exchange with HEPES 0.1 M, and after mixing with the precipitant solution, were recorded between 
200 and 300 nm on a Chirascan CD spectrometer (Applied Photophysics, UK) at 20 °C with a 1 nm bandwidth 
resolution and current time-per-point of 3 s. 100 μL of mAbs solution were added in a 0.1 mm path-length quartz 
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cuvette that was placed in the spectrophotometer. Typically, three scans were recorded and baseline spectra were 
subtracted from each spectrum. Data were processed using Applied Photophysics Chirascan Viewer.
Melting point and Z-potential assessment by DLS. Thermal stability (melting temperature, Tm) of 
protein solutions was assessed by a Zetasizer Nano ZS instrument (Malvern) equipped with a 4 mW He–Ne laser 
at 632.8 nm and a detector placed at 173° in agreement to the proprietary NIBS (Non Invasive Back Scatter) tech-
nology. Samples were placed in quartz cuvettes (1 cm path-length), heated by a Peltier module and the average 
hydrodynamic diameter was measured as a function of temperature from 20 °C to 90 °C (temperature increment 
0.5 °C). DLS can monitor the thermal denaturation of proteins, which leads to irreversible loss of their structure 
and function as the protein unfolds. When the average protein size is observed by DLS versus temperature, one 
will observe a significant increase in the average protein size for temperatures larger than the aggregation point, 
which is generally assumed as the onset of protein melting point.
For the Z-potential evaluations, the appropriate ratios of protein and buffer solutions were placed in dispos-
able folded capillary cells (DTS 1070, Malvern), and then inserted into the Zetasizer instrument. The Z-potential 
was measured by laser Doppler micro-electrophoresis. Briefly, an electric field was applied to the protein solution 
and consequently each molecule moved with a velocity related to its Z-potential. The velocity was measured using 
a laser interferometric technique (M3-Phase analysis light scattering), which allowed the calculation of the elec-
trophoretic mobility, and from this, the average Z-potential and Z-potential distribution.
Light scattering measurements. Static and dynamic light scattering measurements were performed on 
protein solution samples with a concentration between 0.1 and 5.0 mg mL−1 in different crystallization cocktails. 
The Anti-CD20 concentration in these solutions was checked by measurement of the absorbance at 280 nm. 
All the solutions were filtered on a 0.22 µm filter (Anotop 10, Whatman) before measurement. The samples 
were placed in quartz ultra-low volume cuvettes (ZEN 2112, optical path 3 mm, Malvern) to measure with the 
Zetasizer Nano ZS instrument (Malvern) in static mode for the second virial coefficient B22 or dynamic mode 
for the protein diffusion coefficient Dm. The light intensity and its time autocorrelation function were measured 
at 173° scattering angle. All measurements were performed at 20 °C after 2 min of equilibration using automatic 
time settings.
The Debye plots were generated by using Debye’s light scattering equation:
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where n is the solvent refractive index, dn/dc is the refractive index increment, λ is the wavelength of the incident 
light, and NA is Avogadro’s number. The second virial coefficient B22 [mL mol g−2] was obtained from the slope of 
the linear Debye plot of KC/Rθ versus protein concentration C.
The static light scattering results for B22 were accepted if the following criteria were satisfied:
 1. Signal to noise ratio >130%, where noise is solvent kcounts;
 2. Increasing trend for signal kcounts vs. protein concentration.
The interaction parameter kd [mL mg−1] and the self-diffusion coefficient Ds [m2 s−1] were determined by 
using linear fitting of the protein diffusion coefficient Dm, determined from the dynamic light scattering measure-
ments, plotted against the protein concentration C [mg mL−1], using the following Eq. 3 31:
= +D D k C(1 ) (3)m s d
The determined interaction parameter kd can be interpreted as the difference between a thermodynamic term 
related to the product 2B22·MW and a hydrodynamic term (ξ1 + ν):
ξ υ= − +k B M2 ( ) (4)d W22 1
where ξ1 is obtained from the virial expansion of the concentration-dependent frictional coefficient and ν is the 
solvent viscosity.
Solutions that showed turbidity, indicating phase separation and crystallization/precipitation, were not used 
for measurements.
Protein partitioning measurements. Anti-CD20 repartition between aqueous and PEG phases has been 
estimated by the method described by Kress et al.32. A solution (5 mL) containing Na2SO4 1.1 M (13.54 wt.%) 
and PEG400 10.46% V/V (10.22 wt.%) in HEPES 0.1 M at pH 7.4, was added with 200 μL Anti-CD20 solution 
10.3 mg mL−1 in the same buffer. After vigorous stirring for 5 minutes by vortex, the mixture has been left to rest 
overnight. The concentration of the protein in the two separated phases visually detected and in presence of 
excess of precipitated protein, was then assessed by UV spectrophotometry at 280 nm.
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Results and discussion
Anti-CD20 crystallization and crystals analysis. Anti-CD20 needle-like crystals (Fig. 1a) appear by 
sitting-drop vapour diffusion crystallization experiments using a 1:1 volume ratio mixture of a 20 mg mL−1 pro-
tein solution in HEPES buffer 0.1 M at pH 7.4 and a precipitant solution containing PEG400 9.6% V/V (9.4 wt.%) 
and Na2SO4 0.86 M (10.6 wt.%) in the same buffer. Therefore, the initial composition of the drop in the vapour 
diffusion tests corresponds to 10 mg mL−1 Anti-CD20, 4.8% V/V PEG400, 0.43 M Na2SO4 in 0.1 M HEPES at a pH 
of 7.4 and is shown by the diamond symbol in Fig. 2. The crystals appear when the volume of the drop is nearly 
halved with respect to its initial volume. Accordingly, the final concentration of the components in the crystalliz-
ing drops is almost doubled that compared to the initial compositions and it is indicated by the pentagon symbol 
of Fig. 2.
Batch experiments in similar solution composition as that for crystallizing drops in the vapour diffusion tests 
(the term “similar” is used since the exact composition of the droplet at the crystallization point under equili-
bration with the reservoir solution it is not known), give also rise to crystals. Therefore, the batch working point 
coincides with the final conditions of the vapour diffusion tests. Since the batch composition does not vary with 
time, due to the absence of solvent evaporation, it is evident that the solution is supersaturated immediately upon 
mixing the protein and precipitant solutions, which results in a shorter crystallization time (12–18 h) than that 
observed with the sitting drop set up (36–48 h).
The UV-Vis and DLS measurements of washed and dissolved crystals confirmed their protein nature. All the 
analysed samples showed an intense band centred at 280 nm, typical of proteins absorption. The size distribution 
analysis by intensities show a single peak near 12 nm, size expected for Anti-CD20 protein molecules33, and a 
polidispersity <20%, indicating a high monodispersity.
Liquid-Liquid Phase Separation (LLPS) is observed nearly simultaneously with, or just prior to, crystals 
appearance (Fig. 1b) both in the vapour diffusion and batch crystallization trials. In accordance with other mAbs 
Figure 1. Optical microscope image of (a) crystalline Anti-CD20 monoclonal antibody obtained by sitting-
drop vapour diffusion method and (b) Liquid-Liquid Phase Separation occurring just prior to crystallization. 
Solution composition near the crystallization point: 20 mg mL−1 Anti-CD20, 9.6% V/V PEG400, 0.86 M Na2SO4 
in 0.1 M HEPES buffer at pH 7.4.
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crystallization studies reported in literature20,34,35, also here it appears that the LLPS is a key step in Anti-CD20 
crystallization.
Crystallization trials, aiming to investigate the effect of precipitant solution composition on crystal quality 
have been also performed by changing the starting amount of PEG400 and/or Na2SO4. As expected, the shape, 
size and density of crystals (number of crystals per unity of volume) are found to depend on buffer composition, 
initial protein concentration and crystallization method (sitting drop or batch). All these parameters have also 
shown to impact on the time required to observe crystallization. Table 1 shows the effect of the salt concentration 
on the crystal appearance for the batch experiments. Needles with a size of nearly 20 µm are the largest crystals 
obtained for starting solutions with 9.6% V/V PEG400 and 0.70–0.80 M Na2SO4. A further increase in Na2SO4 
concentration produces a faster and massive protein nucleation in less than 24 hours and crystals of smaller size 
(<10 µm) with a spherulite-like morphology appear. For a Na2SO4 concentration of 0.9 M or larger, upon mixing 
the solution immediately turns opalescent due to a macroscopic LLPS in the solution, followed by a rapid protein 
precipitation as gel beads. On the opposite side, for the lowest amount of salt (Na2SO4 ≤ 0.65 M), the solutions 
remain clear for months.
Figure 2 shows the experimental state diagram for the system PEG400/Na2SO4/H2O at 20 °C indicating the 
loci of the points related to solution compositions used for batch crystallization tests (circles) of Table 1, together 
with the starting (diamond) and ending (pentagon) solution compositions in vapour diffusion tests. The figure 
also displays the experimental liquid-liquid equilibrium data and the asymptotic fitting to tie-lines data reported 
in ref. 36.
Figure 2. Experimental state diagram for the system PEG400/Na2SO4/H2O at 293.15 K. Squares: experimental 
liquid-liquid equilibrium data from ref. 36; solid line: asymptotic fitting to tie-lines data from ref. 36; circles: batch 
crystallization conditions reported in Table 1; diamond: starting solution composition in vapour diffusion tests; 
pentagon: ending solution composition in vapour diffusion tests; triangles: measurements points for B22; dotted 
line: shifted binodal curve in the presence of Anti-CD20 protein. Solution composition is expressed as weight 
fraction (wt.).
Na2SO4 [M] Crystallization behaviour
Size 
[µm] Shape
0.90
Opalescent solution, 
Instantaneous 
Precipitation
<1 gel beads
0.86
Precipitation/
crystallization in 
12–24 hours
<10 spherulite
0.80 Crystallization in 18–36 hours <20 needle
0.75 Crystallization in 24–48 hours 20 needle
0.70 Crystallization in 24–48 hours 20 needle
0.65 Clear and stable solution — —
0.55 Clear and stable solution — —
Table 1. Mixed solution compositions, crystallization behaviour and crystal appearance in the batch 
crystallization experiments using an Anti-CD20 concentration 20 mg mL−1, 9.6% V/V PEG400 and 100 mM 
HEPES buffer at a pH of 7.4.
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SLS/DLS analysis. The protein stability in several formulation buffers but without precipitating agents (PEG 
and/or Na2SO4), was assessed by DLS, resulting in values for the melting point and Z-potential. As reported in 
Table 2, all samples are characterized by similar values of melting point, Z-potential, intensity weighted mean 
hydrodynamic size Zavg and polydispersion index (PDI). All protein samples show low positive values of the 
Z-potential, indicating a reduced colloidal stability in the various buffer solutions. Nevertheless, due to a PDI 
close to 0.1, all samples can be considered monodisperse. No significant variations were observed in the sample 
aggregation state over time in the range 12–24 h. Accordingly, further SLS/DLS studies were performed by using 
HEPES as formulation buffer since it was used in previously published crystallization protocols30.
To study the aggregation propensity on Anti-CD20 in HEPES buffer and in various PEG400/Na2SO4 solution 
compositions, SLS and DLS measurements were performed on freshly prepared samples allowing to determine 
the second virial coefficient B22 and the interaction parameter kd, respectively. The value of KC/Rθ was determined 
as a function of protein concentration, ranging from 0.1 to 5.0 mg mL−1, by SLS. Results were used to evidence 
the combined effect of PEG400 and Na2SO4 on Anti-CD20 colloidal stability and to compare these results with 
effective crystallization outcomes.
It is well known that the addition of salts can cause an electrostatic double layer around the protein sur-
face charges, which involves a shielding and the reduction of repulsive interactions among macromolecules. 
Furthermore, the salts ions compete with the protein for water molecules and dehydrate the protein (salting out 
effect37), thus inducing aggregation by mainly electrostatic and hydrophobic interactions. On the other side, pol-
ymers such as PEG bring the protein molecules together due to preferential interactions and osmotic potential38. 
Accordingly, the addition of PEG400 or Na2SO4 to Anti-CD20 solutions is expected to increase the aggregation 
aptitude of the protein and facilitate crystallization, as experimentally observed, e.g., in batch crystallization tests 
of Table 1. However, as displayed in Figs. 3 and 4, for increasing amounts of PEG or Na2SO4 when both compo-
nents are present in solution, the B22 moves towards larger positive values, theoretically indicative of an increase 
in repulsive interactions. Furthermore, effective Anti-CD20 crystallization conditions seems to lay outside the 
crystallization slot defined by George and Wilson15.
Both Figs. 3 and 4 show that the combined effect of PEG400 and Na2SO4 has a noteworthy consequence 
on the B22 value. For instance, for the solution containing 0.48 M Na2SO4 in absence of PEG, a B22 value of 
−8.9 × 10−4 mL mol g−2 is obtained (Fig. 3) that is slightly below the crystallization slot. However, when adding 
PEG400 to the solution while keeping salt concentration constant, B22 steeply increases through the crystalliza-
tion window towards positive values already at 3% V/V of PEG.
Buffer Tm [°C] Z-potential [mV] Zavg [nm] PDI
HEPESa 68.5 ± 0.5 2.2 ± 0.7 11.3 ± 0.1 0.10 ± 0.03
Sodium Citrateb 68.5 ± 0.5 1.1 ± 0.2 12.2 ± 0.2 0.04 ± 0.03
TRISc 69.0 ± 0.5 7.0 ± 1.0 12.63 ± 0.03 0.12 ± 0.01
Sodium Citrate/HEPES 
(1:1 Vol) 69.0 ± 0.5 0.19 ± 0.04 13.6 ± 0.2 0.15 ± 0.03
TRIS/HEPES (1:1 Vol) 69.0 ± 0.5 2.3 ± 1.0 12.13 ± 0.03 0.06 ± 0.01
Table 2. Results for melting point (Tm), Z-potential, intensity weighted mean hydrodynamic size (Zavg), and 
polydispersion index (PDI) from formulation buffers screening (Anti-CD20 concentration 20 mg mL−1; aHEPES 
buffer 0.1 M, pH 7.4; bSodium Citrate buffer 0.035 M, NaCl 0.15 M, pH 6.5; cTRIS buffer 0.1 M, NaCl 0.15 M, pH 8.0).
Figure 3. The second virial coefficient B22 as a function of PEG400 volume concentration (XPEG) at a constant 
amount of 0.48 M Na2SO4 in HEPES 0.1 M buffer at pH 7.4. The crystallization slot according to ref. 15 is shown 
in light grey. The solid line is a guide for the eyes.
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The B22 value for the solution containing 4.8% V/V PEG400 in absence of Na2SO4 is found to be slightly posi-
tive (B22 = 1.8 × 10−4 mL mol g−2), becoming negative (B22 = −2.26 × 10−4 mL mol g−2) when increasing PEG400 
up to xPEG = 9.6% V/V without Na2SO4 (Fig. 4). This is in agreement with results from Ahamed et al.39, who 
observed the reduction in solubility for a mAb for increasing amounts of PEG400. Nevertheless, when salt is 
added to the solution ( ≠C 0Na SO2 4 ), the virial coefficient rises steeply with the salt concentration. These observa-tions clearly indicate that a different effect on the measured value of B22 takes place when PEG400 and Na2SO4 are 
combined together, compared to the cases when they are used separately.
Figure 5 shows the effect of pH on B22 for solutions containing PEG400 and Na2SO4. At pH ≤ 7.6, the B22 
remains roughly unchanged (2.28 < B22 < 4.35 × 10−4 mL mol g−2). These positive values are indicative of repul-
sive protein–protein interactions. At a pH of 8.0, the B22 becomes negative (−3.78 × 10−4 mL mol g−2) and then 
sharply increases approaching pH = 8.8, which is the theoretical isoelectric point of Anti-CD20 (pI = 8.8)40.
It is expected that protein-protein interactions at a pH substantially below or above the pI are repulsive, while 
at a pH near the pI they become increasingly attractive due to the overall neutral charge of the protein. However, 
the actual pI of biomolecules might change with ionic environment, and generally decreases at different extents 
with increasing ionic strength, depending on the nature of the counter-ion41,42. It is speculated that in the presence 
of 0.43 M Na2SO4, PEG400 4.8% V/V and 0.1 M HEPES, the effective pI of Anti-CD20 is around 8.0. Therefore, 
for pH < 8.0, the slightly positive B22 values are most likely due to partially screening of the net positive elec-
trostatic charges of protein molecules, while at pH = 8.0, where the net charge becomes null, the net resultant 
Figure 4. The second virial coefficient B22 as a function of Na2SO4 molar concentration (CNa SO2 4) for constant PEG400 volume concentration xPEG = 4.8% V/V in HEPES 0.1 M, pH 7.4. The solid square symbol indicate B22 
for a PEG400 concentration of 9.6% V/V without NaCl. The crystallization slot according to ref. 15 is shown in 
light grey. The solid line is a guide for the eyes.
Figure 5. pH dependence of B22 for Anti-CD20 solutions with 4.8% V/V PEG400, 0.43 M Na2SO4, and HEPES 
0.1 M. The crystallization slot according to ref. 15 is shown in light grey. The solid line is a guide for the eyes.
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interaction is attractive. Above pH 8.0, the B22 values become strongly positive, indicating an ineffective screening 
of the net negative charge of molecules that results in repulsive interactions.
Since solution composition strongly affects protein stability and aggregate formation, the Na2SO4 concentra-
tion dependence of B22 was also investigated at higher PEG and salt concentrations, thus reaching compositions 
close to that used for crystallization experiments of Table 1. Correlation between B22 and Na2SO4 concentration 
is shown in Fig. 6, confirming an increasing trend similar to that observed for lower concentrations of Fig. 4 also 
in this case.
In Fig. 6 it can be seen that the B22 values are negative (attractive interactions) for Na2SO4 concentration 
ranging from 0.55 to 0.6 M, corresponding to conditions in Table 1 that give clear solutions, while they become 
positive (repulsive interactions) when the salt concentration is further increased up to 0.9 M. Within the crystalli-
zation window, i.e. Na2SO4 ranging from 0.7 to 0.86 M, the B22 values range from 3.2 × 10−4 to 5.7 × 10−4 mL mol 
g−2. This would be theoretically indicative of the absence of attractive colloidal interactions, in opposition to the 
results of the crystallization tests.
DLS measurements were then used to determine the interaction parameter kd. Generally, kd and B22 display 
a qualitatively similar trend43. However, looking at the behaviour of the interaction parameter kd in the crys-
tallization range of Fig. 6, negative values are found for xPEG = 9.6% V/V and sodium sulfate 0.55–0.80 M, with 
slight variations within this range. Generally, a negative value of kd implies the existence of attractive interactions 
between protein molecules which slow down their diffusion in solution44. Since under the same conditions B22 is 
negative only for Na2SO4 < 0.6 M and then increases up to 1.23–4.94 × 10−4 mL mol g−2 in the salt concentration 
range 0.6–0.8 M, this indicates that underlying attractive interactions do not have a thermodynamic origin of 
colloidal nature. We can instead conclude that these interactions result from the hydrodynamic effects included 
in the second term of Eq. 4 45, most likely due to the increase of solution viscosity (from 1.949 cP in the PEG400 
9.6% V/V solution without salt to 2.546 cP for PEG400 9.6% V/V and Na2SO4 0.9 M). Nevertheless, as for B22, the 
increasing trend of kd with the concentration of Na2SO4 does not comply with the outcome of crystallization tests. 
In fact, the increase of Na2SO4 concentration at values larger than 0.8 M gives rise to a theoretically significant 
increase of the strength in protein-protein repulsions, according to measured B22, values that are exacerbated near 
the LLPS region, while crystals are obtained in such conditions.
From the observed trends of B22 and kd, we can conclude that neither PEG400 nor Na2SO4 act as conventional 
precipitants for Anti-CD20 when used together since, on average, Anti-CD20 monomers apparently repel one 
another. Nevertheless, this evidently contradicts the experimental outcomes of crystallization tests. The B22 val-
ues are negative (attractive interactions) in formulations that remain clears for months, whereas positive values, 
corresponding theoretically to net repulsive interactions, have been found for the best-performing crystallizing 
or either in precipitating conditions.
Considering the possible variations in their structure, morphology, size, surface charge and chemistry, pro-
teins definitely represent one of the most complex colloidal systems. Several mechanisms could lead to molecular 
aggregation in solution and it is not excluded that more than one is active in certain conditions. Therefore, it is 
not surprising that B22 does not always reflect the aggregation propensities of proteins in a given formulation. 
Several papers can be found in literature reporting discrepancies between B22 and the susceptibility to aggregation 
of structurally complex macromolecules, like monoclonal antibodies43,46. Crystallizing conditions with positive 
B22 values were found for a mAb molecule with PEG400 by Rakel et al.35. This behaviour has been ascribed to 
the ambivalent character of PEG400 as precipitant and stabilizer35,47. Kress et al.48 observed the decrease in B22 of 
an immunoglobulin G (IgG) when increasing PEG2000, sodium citrate and NaCl solute concentration, if used 
separately. However, the mutual effect of PEG and salts resulted in a shift of B22 from negative to almost neutral 
values when increasing the NaCl amount if used together32. This behaviour has been explained by a solubilizing 
effect of IgG in PEG2000 induced by NaCl until a maximum salt concentration. Exceeding this NaCl value, a 
solid-liquid equilibrium, due to protein precipitation, was observed. Herhut et al.49 measured B22 for an IgG and 
Figure 6. B22 and kd as a function of Na2SO4 concentration for xPEG = 9.6% V/V and pH 7.4. The experimental 
crystallization window boundaries (see Table 1) are highlighted by the dotted vertical lines. The solid lines are 
guides for the eyes.
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D-xylose ketol-isomerase (172.3 kDa) with ammonium sulphate and PEG12000 and PEG2000, respectively. They 
observed the initial decrease in B22 at low PEG concentration, passing through a minimum and then increasing 
for higher PEG concentrations. This behaviour has been explained by considering that polymer-induced interac-
tions are not solely attractive over the whole polymer concentration range. Normally, polymer chains behave as 
coil-inducing attractive interactions between protein molecules at low-polymer concentration. However, at high 
polymer concentration, flexible coils elongate and enter space between the proteins, so that repulsive interaction 
are induced50,51. This explanation has been also confirmed by molecular dynamic simulations at different polymer 
concentration by Cao et al.52.
It has also been reported that conformational stability plays an important role in aggregation propensity, with 
partially unfolded conformational intermediates being responsible of aggregate formation9. In this case, the B22 
value is unlikely to correlate with long-term aggregation because the structurally perturbed state susceptible to 
aggregation could be present in a small fraction of molecules compared to the native species46. Aiming to shed 
light on this aspect, protein structure in solution has been investigated in the present work.
protein structure in the solution. On the bases of the results above, measurements of melting temper-
ature (Tm) for several solution compositions, including xPEG = 9.6% V/V and Na2SO4 at various concentrations, 
and Circular Dichroism (CD) in selected formulations, were performed aiming to investigate conformational 
stability of Anti-CD20. Results show slight variations of the melting points: Tm = 67.0, 67.5, 68.0, and 67.5 ± 0.5 °C 
for 0.55, 0.65, 0.75, and 0.85 M Na2SO4, respectively, confirming that samples, on average, share similar water 
activity according to the Wyman-Tanford equation53.
Circular Dichroism spectra of protein solutions give information on the secondary structure, folding proper-
ties and conformational variation of the proteins54. The general shape of the spectrum of the provided Anti-CD20 
solution (Fig. 7, initial conditions) corresponds to the expected spectra for Anti-CD20, as it shows the typical 
shape of a monoclonal antibody with a minimum around 220 nm and a maximum around 200 nm, suggesting 
a secondary structure dominated by β-sheet motif54. Moreover, these spectra correspond to the CD-spectra of 
Anti-CD20 from literature55.
These spectra show that the protein is well folded in every buffer, i.e. the 3D-structure of Anti-CD20 is pre-
served under all conditions tested. However, the maximum ellipticity (around 200 nm) is much higher after the 
buffer exchange (red and green spectra in Fig. 7) than in the initial buffer (blue spectrum), while ellipticity at 
other wavelengths is similar in every buffer. This suggest that the β-sheet motifs of the mAbs are favoured and 
stabilized in the new HEPES buffer, in comparison to the initial buffer (0.025 M sodium citrate at pH 6.5 and 
0.154 M sodium chloride).
There is no significant difference in the far-UV CD spectra of Anti-CD20 before (Fig. 7, red spectrum) and 
after the addition of Na2SO4 and PEG400 as precipitating agents (Fig. 7, green spectrum), although a small shift 
can be observed, showing slight changes in the 3D-structure. The main difference between these spectra is around 
230 nm, but the peak is quite narrow and this wavelength does not correspond to any typical feature of protein 
structure. Therefore, the difference could be due to Na2SO4 or PEG400 absorbance or might be due to some noise. 
It should be noted, though, that the crystallization solution had to be diluted in order to enable CD measurement. 
Since the spectra before and after the concentrated crystallization conditions are the same, it can be concluded 
that the concentrated crystallization conditions do not alter the secondary structure of the protein.
The Anti-CD20 secondary structure is preserved after centrifugation and addition of the precipitating agents, 
as the typical β-sheet motif appears clearly in the spectrum (Fig. 7, green spectrum). Moreover, this secondary 
structure seems to be favoured in the crystallization buffer, meaning that the 0.1 M HEPES at pH 7.4 buffer 
promotes Anti-CD20 crystallization by making the secondary structure less flexible. However, no clear effect of 
Na2SO4 or PEG400 on the Anti-CD20 secondary structure is visible.
The role of LLPS in Anti-CD20 crystallization. A complementary scenario can be envisioned when 
considering LLPS phenomena observed concurrently or just prior of Anti-CD20 crystallization.
For simple protein/salts or protein/PEG systems, it has been often reported that the B22 value can be used as a 
predictor of LLPS formation, since weak protein-protein interactions, in general hydrophobic in nature or even 
limited to specific protein chain sequences, are at the origin of the phase separation22. However, our results seem 
to suggest that the LLPS (observed just prior or at the point of protein crystallization) proceeds without attractive 
interactions, since B22 is negative when a mono-phase system is observed while it turns positive as approaching 
the liquid phase separation and crystals formation.
It could be argued that, in our complex mixture that includes several components, the B22 values fail to predict 
the experimentally observed crystallization since it may be rather related to the polymer-salt phase separation 
that can occur without protein. The liquid-liquid separation of PEG/salt aqueous solutions is a fundamentally 
different phenomenon from PEG/protein or salt/protein LLPS, which originate by a combination of hydropho-
bic and salting-out effects, whose origin has been attributed to the different conformations of the PEG polymer 
chain in aqueous solution and their respective hydration24. Actually, the PEG400/Na2SO4/H2O system is known 
to generate aqueous two-phase systems36,56,57. Figure 2 displays the experimental binodal curve together with 
liquid-liquid equilibrium tie-lines data for PEG400 + Na2SO4 + H2O system at 293.15 K (the temperature used in 
this work for crystallization experiments and SLS/DLS measurements)36.
Concerning the specific system studied in this work, for a protein concentration of 20 mg mL−1 and a PEG400 
content of 9.6% V/V (9.4 wt.%), phase separation is observed for salt concentrations ≥0.7 M (≥8.6 wt.%) (crys-
tallization points of Table 1 and dark circles in Fig. 2), that is quite far from both binodal curve. However, the 
presence of the protein can reduce the amount of salt needed for observing LLPS in the multicomponent PEG/
salt/protein/water systems24. Consequently, it cannot be excluded that the effective binodal curve for PEG/salt 
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LLPS is shifted down to conditions corresponding to the observed crystallization points, in a region of poor 
solvent conditions, thus giving a decisive contribute to the aggregation/crystallization behaviour of Anti-CD20.
Figure 8 shows the change in turbidity (Residual Intensity) for a solution containing PEG400 9.6% V/V in 
0.1 M HEPES at pH 7.4 and increasing amount of Na2SO4. It is observed that, in absence of the Anti-CD20, a 
sharp increase in solution turbidity is observed for salt concentration >1.1 M (>13.5 wt.%), that is very close to 
the binodal curve reported in Fig. 2 for the PEG400 + Na2SO4 + H2O system. Since in the presence of the protein 
turbidity due to liquid-liquid phase separation is observed for salt concentration larger than 0.65 M for the same 
amount of PEG, this proves the shift of LLPS region towards lower values of PEG and/or salt components when 
Anti-CD20 is present in the solution.
It is worth noting that B22 measurements reported in Figs. 3 and 4 have been made in a region of Fig. 2 where 
LLPS (and crystallization) are not observed (triangles in the left-bottom side of the figure). This means that PEG/
salt LLPS is not responsible for the contradiction between B22 measurements and the outcome of crystallization 
trials, but rather the intrinsic complexity of the system makes ineffective the measurement of the osmotic coeffi-
cient as predictor parameter for crystallization conditions.
According to our results, it can be proposed that PEG/salt LLPS causes the preferential partitioning of pro-
teins in a specific salt- or PEG-rich phase. In general, the affinity of the protein for the polymeric component, 
due to hydrophobic interactions, favours the protein concentration in the PEG-rich phase39,58. This is particularly 
true for PEG400, which is a low molecular weight polymer and, therefore, its size exclusion effects on proteins 
Figure 7. Far-UV CD spectra of Anti-CD20 under initial conditions (blue spectra, mAbs concentration 
9.95 mg mL−1 in stock buffer), after buffer exchange with HEPES 0.1 M pH 7.4 (red spectra, mAb concentration 
100 mg/mL in crystallization buffer) and after salt mixing (green spectra, mAb concentration 60 mg/mL in 
crystallization buffer and with 0.9 M Na2SO4 and 9.6% V/V PEG400).
1 1Scientific RepoRtS |         (2020) 10:8902  | https://doi.org/10.1038/s41598-020-65776-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
are negligible while the dominant factor in the separation is the salting out effect, produced by the sulphate, 
which causes the protein to migrate to the PEG-rich phase. This effect has been confirmed by measurements on 
Anti-CD20 partitioning, showing that more than 90% of the solution protein migrates in the PEG-rich phase in 
the protein-saturated Anti-CD20/PEG400/Na2SO4/HEPES/H2O mixture displaying phase separation.
In such conditions, during LLPS, the Anti-CD20 concentrates in droplets that have a density higher than the 
average density of the whole system thus generating a much higher supersaturation. When the protein concen-
tration exceeds a certain limit, precipitation at the interface is observed and the precipitated protein is in equi-
librium with the protein solubilised in each phase59. For particularly high Anti-CD20 (>30 mg mL−1 or PEG/salt 
concentrations (i.e. PEG400 9.4 wt.% and Na2SO4 ≥ 11.1 wt.%), these droplets look not to be as liquid, having 
instead the appearance of gel beads. Protein crystals initiate to nucleate and grow near the boundary of the most 
protein-concentrated droplets (Fig. 9), suggesting that the droplet interface participates in the nucleation mech-
anism60. Subsequently, crystals appear within the bulk of the droplets, which spread and coalesce. Many droplets 
disappear as crystal growth proceeds, suggesting that a continuous exchange exists between the droplets and the 
surrounding medium.
Experimental observations clearly indicate the important role of LLPS and of the established liquid-liquid 
interface in inducing Anti-CD20 nucleation, even in absence of underlying net attractive interaction between 
proteins. It is likely that only protein molecules distributed at the droplets interface experience local short-range 
attractive interactions, due to the specific environment and/or conformational changes, not influencing the mean 
B22 value.
On the basis of our results, it could be hypothesized that the occurrence of LLPS in crystallizing/precipitating 
conditions results in a partially unfolded protein conformation or in a suitable variation of the secondary/tertiary 
protein structure, as already reported in other cases27, which can be the species prone to aggregation through a 
mechanism driven by conformational change rather than colloidal interactions, and which initiate the crystalli-
zation process. The conformationally perturbed protein can be a minor species, which does not alter significantly 
the predominant native protein population and only slightly contributes to the net protein–protein interaction 
value measured by B22. Indeed, SLS is an integrative technique, which provides only averaged information. If only 
specific short-range orientations or aggregation-prone structurally perturbed states can lead to attractive interac-
tions, the remaining repulsive orientations or species dominate in the light scattering results.
It is important to note that the measurements of intermolecular interactions were performed under low pro-
tein concentration conditions (≤5 mg mL−1), while crystallization trials are generally conducted at higher con-
centrations (≥20 mg mL−1). Both B22 and kd determined in dilute conditions are considered generally predictive 
of high-concentration behaviour. Nonetheless, high concentration behaviour can differ from that observed at 
dilute conditions, since “crowding” effects, i.e. the increased chance of molecular interactions, deviation from 
thermodynamic ideality and higher-order interactions (e.g., B23, B222) can significantly alter the net inter-protein 
interactions55,61. The contribution of these effects to aggregation propensity of structurally complex molecules 
such as mAbs, cannot be ruled out.
conclusions
This work reports about the study of Anti-CD20 (a full-length monoclonal antibody) crystallization in a PEG400/
Na2SO4/H2O system occurring near LLPS conditions. The DLS/SLS studies performed to verify the correlation 
between the second virial coefficient and molecular diffusivity with the protein aggregation propensity in selected 
solution formulations indicates that B22 remains strongly positive (a sign of repulsive protein–protein interac-
tions) for all conditions that have been instead ascertained to be effective for protein crystallization or precip-
itation. For all the crystallizing or precipitating conditions, the occurrence of LLPS phenomena was observed 
concomitantly or near the nucleation stage. Even in this case, the second virial coefficient does not correlate with 
Figure 8. Residual Intensity measured by DLS at a fixed scattering angle of 173° for a solution containing 
PEG400 9.6% V/V in 0.1 M HEPES at pH 7.4 and increasing amount of Na2SO4, without protein. The solid line 
is a guide for the eyes.
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the LLPS, which mainly proceeds without attractive protein interactions, and that may be rather related to the 
polymer-salt phase separation that can occur without protein. The possible interplay between the salt/PEG and 
protein/PEG phase separation, which can affect the solvent quality, can have a role on the polymer mediated 
forces and finally on Anti-CD20 aggregation. On the basis of these measurements and the experimental obser-
vation of LLPS near the nucleation zone, it is proposed that a minor population of protein molecules can experi-
ence valuable protein-protein attractive interactions, induced by local environmental factor, slightly affecting the 
averaged B22 parameter.
Received: 28 October 2019; Accepted: 30 April 2020;
Published: xx xx xxxx
References
 1. Cromwell, M. E. M., Hilario, E. & Jacobson, F. Protein aggregation and bioprocessing. AAPS J. 8, E572–E579 (2006).
 2. Thömmes, J. & Etzel, M. Alternatives to chromatographic separations. Biotechnol. Prog. 23, 42–45 (2007).
 3. Low, D., O’Leary, R. & Pujar, N. S. Future of antibody purification. J. Chromatogr. B 848, 48–63 (2007).
 4. Dos Santos, R., Carvalho, A. L. & Roque, A. C. Renaissance of protein crystallization and precipitation in biopharmaceuticals 
purification. Biotechnol. Adv. 35, 41–50 (2017).
 5. Yin Chan, H. & Lubchenko, V. A mechanism for reversible mesoscopic aggregation in liquid solutions. Nat. Commun. 10, 2381, 
https://doi.org/10.1038/s41467-019-10270-5 (2019).
 6. Chari, R., Jerath, K., Badkar, A. V. & Kalonia, D. S. Long- and short-range electrostatic interactions affect the rheology of highly 
concentrated antibody solutions. Pharm. Res. 26, 2607–2618 (2009).
 7. Alford, J. R. et al. High concentration formulations of recombinant human Interleukin-1 receptor antagonist: I. Physical 
characterization. J. Pharm. Sci. 97, 3035–3050 (2008).
 8. Mahler, H. C., Friess, W., Grauschopf, U. & Kiese, S. Protein aggregation: pathways, induction factors and analysis. J. Pharm. Sci. 98, 
2909–2934 (2009).
 9. Chi, E. Y., Krishnan, S., Randolph, T. W. & Carpenter, J. F. Physical stability of proteins in aqueous solution: mechanism and driving 
forces in nonnative protein aggregation. Pharm. Res. 20, 1325–1336 (2003).
 10. Wang, J. et al. Magic number colloidal clusters as minimum free energy structures. Nat. Commun. 9, 5259, https://doi.org/10.1038/
s41467-018-07600-4 (2018).
 11. Yadav, S., Shire, S. J. & Kalonia, D. S. Factors affecting the viscosity in high concentration solutions of different monoclonal 
antibodies. J. Pharm. Sci. 99, 4812–4829 (2010).
 12. Roberts, C. J., Das, T. K. & Sahin, E. Predicting solution aggregation rates for therapeutic proteins: approaches and challenges. Int. J. 
Pharm. 418, 318–333 (2011).
 13. Velev, O. D., Kaler, E. W. & Lenhoff, A. M. Protein interactions in solution characterized by light and neutron scattering: comparison 
of lysozyme and chymotrypsinogen. Biophys. J. 75, 2682–2697 (1998).
 14. Neal, L. B., Asthagiri, D. & Lenhoff, A. M. Molecular origins of osmotic second virial coefficients of proteins. Biophys. J. 75, 
2469–2477 (1998).
 15. George, A. & Wilson, W. W. Predicting protein crystallization from a dilute solution property. Acta Crystallogr. D. 50, 361–365 
(1994).
 16. Haas, C. & Drenth, J. The protein-water phase diagram and the growth of protein crystals from aqueous solution. J. Phys. Chem. B 
102, 4226–4232 (1998).
 17. Salgın, S., Salgın, U. & Bahadır, S. Zeta Potentials and Isoelectric Points of Biomolecules: The Effects of Ion Types and Ionic 
Strengths. Int. J. Electrochem. Sci. 7, 12404–12414 (2012).
 18. Hassan, P. A., Rana, S. & Verma, G. Making sense of Brownian motion: colloid characterization by dynamic light scattering. 
Langmuir 31, 3–12 (2015).
 19. Harding, S. E. & Johnson, P. The concentration-dependence of macromolecular parameters. Biochem. J. 231, 543–547 (1985).
 20. Trilisky, E., Gillespie, R., Osslund, T. D. & Vunnum, S. Crystallization and Liquid-Liquid Phase Separation of Monoclonal 
Antibodies and Fc-Fusion Proteins: Screening Results. Biotechnol. Prog. 27, 1054–1067 (2011).
 21. Muschol, M. & Rosenberger, F. Liquid–liquid phase separation in supersaturated lysozyme solutions and associated precipitate 
formation/crystallization. J. Chem. Phys. 107, 1953, https://doi.org/10.1063/1.474547 (1997).
 22. Wolf, M. et al. Effective interactions in protein–salt solutions approaching liquid–liquid phase separation. J. Molec. Liq. 200, 20–27 
(2014).
 23. Lewus, R. A., Darcy, P. A., Lenhoff, A. M. & Sandler, S. I. Interactions and Phase Behavior of a Monoclonal Antibody. Biotechnol. 
Prog. 27, 280–289 (2011).
 24. Dumetz, A. C., Lewus, R. A., Lenhoff, A. M. & Kaler, E. W. Effects of ammonium sulfate and sodium chloride concentration on PEG/
protein liquid-liquid phase separation. Langmuir 24, 10345–10351 (2008).
Figure 9. Protein crystals nucleating near the boundary of the droplets (a) and crystals forming within the bulk 
of the droplets (b,c).
13Scientific RepoRtS |         (2020) 10:8902  | https://doi.org/10.1038/s41598-020-65776-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
 25. Lomakin, A., Asherie, N. & Benedek, G. B. Monte Carlo study of phase separation in aqueous protein solutions. J. Chem. Phys. 104, 
1646, https://doi.org/10.1063/1.470751 (1996).
 26. ten Wolde, P. R. & Frenkel, D. Enhancement of Protein Crystal Nucleation by Critical Density Fluctuations. Science 277, 1975–1978 
(1997).
 27. Chen, Q., Vekilov, P. G., Nagel, R. L. & Hirsch, R. E. Liquid-Liquid Phase Separation in Hemoglobins: Distinct Aggregation 
Mechanisms of the b6 Mutants. Biophys. J. 86, 1702–1712 (2004).
 28. Wedekind, J. et al. Optimization of crystal nucleation close to a metastable fluid-fluid phase transition. Sci. Rep. 5, 11260, https://doi.
org/10.1038/srep11260 (2015).
 29. Yang, M. X. et al. Crystalline monoclonal antibodies for subcutaneous delivery. PNAS 100, 6934–6939 (2003).
 30. Yang, H. et al. Optimization of Vapor Diffusion Conditions for Anti-CD20 Crystallization and Scale-Up to Meso Batch. Crystals 9, 
230, https://doi.org/10.3390/cryst9050230 (2019).
 31. Zhang, J. & Liu, X. Y. Effect of protein-protein interactions on protein aggregation kinetics. J. Chem. Phys. 119, 10972–10976 (2003).
 32. Kress, C. & Brandenbusch, C. Osmotic virial coefficients as access to the protein partitioning in aqueous two-phase systems. J. 
Pharm. Sci. 104, 3703–3709 (2015).
 33. AMECRYS Project, Deliverable D5.1 Simulation code for thermodynamics of course-grained model of mAbs in confined geometry, 
http://www.amecrys-project.eu/images/documents/AMECRYS–Deliverable-D5.1.pdf, https://doi.org/10.5281/zenodo.1042207 
(2017).
 34. Hildebrandt, C., Mathaes, R., Saedler, R. & Winter, G. Origin of Aggregate Formation in Antibody Crystal Suspensions Containing 
PEG. J. Pharm. Sci. 105, 1059–1065 (2016).
 35. Rakel, N., Galm, L., Bauer, K. C. & Hubbuch, J. Influence of macromolecular precipitants on phase behavior of monoclonal 
antibodies. Biotechnol. Prog. 31, 145–153 (2015).
 36. de Araujo Sampaio, D. et al. Aqueous two-phase (polyethylene glycol + sodium sulfate) system for caffeine extraction: Equilibrium 
diagrams and partitioning study. J. Chem. Thermodyn. 98, 86–94 (2016).
 37. Roberts, D. et al. Specific Ion and Buffer Effects on Protein−Protein Interactions of a Monoclonal Antibody. Mol. Pharmaceutics 12, 
179–193 (2015).
 38. Arakawa, T. & Timasheff, S. N. Mechanism of poly(ethylene glycol) interaction with proteins. Biochemistry 24, 6756–6762 (1985).
 39. Ahamed, T. et al. Phase Behavior of an Intact Monoclonal Antibody. Biophys. J. 93, 610–619 (2007).
 40. AMECRYS Project, Deliverable D2.2 HEL4 domain fragment & Anti-CD20 mAb process specification report, p. 20, http://www.
amecrys-project.eu/images/documents/AMECRYS–Deliverable-D2.2.pdf.
 41. Quigley, A. & Williams, D. R. The second virial coefficient as a predictor of protein aggregation propensity: A self-interaction 
chromatography study. Europ. J. Pharmac. Biopharm. 96, 282–290 (2015).
 42. Salgın, S., Salgın, U. & Bahadır, S. Zeta Potentials and Isoelectric Points of Biomolecules: The Effects of Ion Types and Ionic 
Strengths. Int. J. Electrochem. Sci. 7, 12404–12414 (2012).
 43. Saito, S. et al. Behavior of monoclonal antibodies: relation between the second virial coefficient (B(2)) at low concentrations and 
aggregation propensity and viscosity at high concentrations. Pharm. Res. 29, 397–410 (2012).
 44. Wu, G. et al. Elucidating the weak protein-protein interaction mechanisms behin d the liquid-liquid phase separation of a mAb 
solution by different types of additives. Euro. J. Pharm. Biopharm. 120, 1–8 (2017).
 45. Sorret, L. L., DeWinter, M. A., Schwartz, D. K. & Randolph, T. W. Challenges in Predicting Protein-Protein Interactions from 
Measurements of Molecular Diffusivity. Biophys. J. 111, 1831–1842 (2016).
 46. Bajaj, H. et al. Protein structural conformation and not second virial coefficient relates to long-term irreversible aggregation of a 
monoclonal antibody and ovalbumin in solution. Pharm. Res. 23, 1382–1394 (2006).
 47. Peat, T. S., Christopher, J. A. & Newman, J. Tapping protein data bank for crystallization information. Acta Crystallogr. D. 61, 
1662–1669 (2005).
 48. Kress, C., Sadowski, G. & Brandenbusch, C. Solubilization of proteins in aqueous two-phase extraction through combinations of 
phase-formers and displacement agents. Europ. J. Pharm. Biopharm. 112, 38–44 (2017).
 49. Herhut, M., Brandenbusch, C. & Sadowski, G. Inclusion of mPRISM potential for polymer-induced protein interactions enables 
modeling of second osmotic virial coefficients in aqueous polymer-salt solutions. Biotechnol. J. 11, 146–154 (2016).
 50. Vivares, D., Belloni, L., Tardieu, A. & Bonneté, F. Catching the PEG induced attractive interaction between proteins. Eur. Phys. J. E 
9, 15–25 (2002).
 51. Kozer, N., Kuttner, Y. Y., Haran, G. & Schreiber, G. Protein-protein association in polymer solutions: From dilute to semidilute to 
concentrated. Biophys. J. 92, 2139–2149 (2007).
 52. Cao, X. Z., Merlitz, H., Wu, C. X. & Sommer, J. U. Polymer-induced entropic depletion potential. Phys. Rev. E 84, 041802, https://doi.
org/10.1103/PhysRevE.84.041802 (2011).
 53. Miyawaki, O., Dozen, M. & Nomura, K. Thermodynamic analysis of osmolyte effect on thermal stability of ribonuclease A in terms 
of water activity. Biophys. Chem. 185, 19–24 (2014).
 54. Manavalan, P. & Johnson, W. C. Sensitivity of circular dichroism to protein tertiary structure class. Nature 305, 831–832 (1983).
 55. Lee, H. K. et al. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product. MAbs 10, 380–396 
(2018).
 56. Martins, J. P. et al. Liquid-Liquid Equilibrium of Aqueous Two-Phase System Composed of Poly(ethylene glycol) 400 and Sulfate 
Salts. J. Chem. Eng. Data 55, 1247–1251 (2010).
 57. Nascimento, G. R. et al. Liquid−Liquid Equilibrium of Two-Phase Aqueous Systems Composed of PEG 400, Na2SO4, and Water at 
Different Temperatures and pH Values: Correlation and Thermodynamic Modeling. J. Chem. Eng. Data 63, 1352–1362 (2018).
 58. Asenjo, J. A. & Andrews, B. A. Aqueous two-phase systems for protein separation: Phase separation and applications. J. Chromatogr. 
A. 1238, 1–10 (2012).
 59. Asenjo, J. A. & Andrews, B. A. Aqueous two-phase systems for protein separation: A perspective. J. Chromatogr. A 1218, 8826–8835 
(2011).
 60. Kuznetsov, Y. G., Malkin, A. J. & McPherson, A. The liquid protein phase in crystallization: a case study - intact immunoglobulins. 
J. Cryst. Growth 232, 30–39 (2001).
 61. Blanco, M. A., Perevozchikova, T., Martorana, V., Manno, M. & Roberts, C. J. Protein–Protein Interactions in Dilute to Concentrated 
Solutions: α-Chymotrypsinogen in Acidic Conditions. J. Phys. Chem. B 118, 5817–5831 (2014).
Acknowledgements
Authors would like to thank the European Union’s Horizon 2020 FET-OPEN research and innovation program 
for funding this work within the AMECRYS project (http://www.amecrys-project.eu) under grant agreement 
n. 712965. Anti-CD20 monoclonal antibody was kindly provided by FUJIFILM Diosynth Biotechnologies 
(Billingham, UK). J.H.t.H, M.L.B. and C.J.J.G. would like to acknowledge that this work was carried out in 
the CMAC National Facility supported by UKRPIF (UK Research Partnership Fund) award from the Higher 
Education Funding Council for England (HEFCE) (Grant ref. HH13054).
1 4Scientific RepoRtS |         (2020) 10:8902  | https://doi.org/10.1038/s41598-020-65776-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
Author contributions
E.P. and F.P.N. performed DLS/SLS measurements and analysed data. T.F.M., E.P. and M.L.B performed 
crystallization experiments. C.J.J.G., M.L.B. and J.H.t.H. performed CD measurements and analysed results. E.C. 
contributed to analyze experimental DLS/SLS data. T.F.M. and G.D.P. prepared the main manuscript text. E.P. and 
T.F.M. prepared figures. G.D.P. and F.P.N. conceived the work. G.D.P. coordinated the work. All authors reviewed 
the manuscript.
Competing interests
The authors declare no competing interests.
Additional information
Correspondence and requests for materials should be addressed to F.P.N. or G.D.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
